The investigation began in the clinic. Within the prospective NOFF-S cohort, recruited through the Stroke Unit of the University Hospital Essen since October 2022, the researchers compared 26 patients who developed stroke-associated pneumonia with 326 who did not. Patients with pneumonia had more severe strokes at admission, measured by the National Institutes of Health Stroke Scale, and their 90-day outcome on the modified Rankin Scale was markedly worse. Pneumonia predicted poor outcome with a relative risk of 3.2 in both univariate and multivariable analyses, and the risk only modestly declined after adjustment for age, sex, and initial stroke severity. Flow cytometry of blood samples revealed something equally striking: patients who developed pneumonia showed a long-lasting deregulation of neutrophil subsets, with reduced proportions of CD15-low neutrophils persisting even three months after the stroke, hinting that the immune disturbance triggered by pneumonia was not a transient event.

To dissect mechanisms, the team turned to mice. They induced a transient 30-minute occlusion of the middle cerebral artery and, three days later, instilled Streptococcus pneumoniae directly into the trachea, replicating the typical timing of pneumonia onset in stroke patients. The results were dramatic. Pneumonia did not enlarge the initial infarct, but it significantly worsened neurological deficits, increased brain edema, and broke down the blood-brain barrier, as evidenced by increased IgG extravasation into the ischemic tissue. It also amplified the expression of the adhesion molecule ICAM-1 on cerebral microvessels, boosted infiltration of CD45-positive leukocytes, increased the density of platelet-rich microvascular thrombi marked by glycoprotein-Ib-alpha, and left behind extranuclear deposits of histone-H4 in the previously ischemic striatum, including in microglia and macrophages. A more severe 60-minute stroke model reproduced the same pattern, confirming that the findings were not an artifact of mild ischemia.

Perhaps the most sobering result concerned standard care. Amoxicillin, started three hours after infection and repeated every eight hours, reduced the bacterial load in the lungs and partially restored blood-brain barrier integrity and microvascular thrombosis. Yet it failed to improve neurological deficits, did not reduce the flood of neutrophils, monocytes, T cells, B cells, and NK cells invading the ischemic brain, and left extranuclear histone deposits untouched. This mirrors the disappointing record of prophylactic antibiotics in large randomized stroke trials such as STROKE-INF and PASS, which consistently failed to improve outcome despite reducing infection rates. Infection control, the study makes clear, is not the same as controlling the inflammatory fallout of infection.

Proteomic analysis of sorted blood neutrophils revealed why. Among 1,058 detected proteins, pneumonia shifted the neutrophil proteome toward a signature of degranulation, platelet activation, and NETosis, the explosive process by which neutrophils eject web-like structures of DNA studded with antimicrobial and tissue-damaging proteins. Twelve proteins were regulated in opposite directions by pneumonia and amoxicillin, including the chromatin-remodeling protein RUVBL1 and the histone H2B family member HIST2H2BB, interpreted as markers of ongoing NETosis and prior histone release. Notably, TOLLIP, a positive regulator of chronic inflammation known to exacerbate ischemic brain injury, rose with pneumonia and resisted amoxicillin, indicating a proinflammatory program that antibiotics alone cannot switch off.

With neutrophils implicated, the researchers tested a series of interventions. Depleting neutrophils with an anti-Ly6G antibody reversed the pneumonia-driven blood-brain barrier breakdown, brain edema, and microvascular thrombosis, establishing neutrophils as central mediators. But neutrophils are also essential for bacterial clearance, and post-stroke immunosuppression already compromises adaptive immunity, so depletion is not a clinically viable option. The team therefore targeted neutrophil products instead. Degrading existing neutrophil extracellular traps with DNase-I did nothing to help and actually increased hemorrhagic transformation of the infarcts, suggesting that NET DNA helps seal fragile ischemic vessels. Blocking NET formation with the gasdermin-D inhibitor LDC7559, or inhibiting the NET-bound enzyme myeloperoxidase with AZD4831, each reduced brain edema and microvascular thrombosis, but neither restored neurological function when given at the time of pneumonia.

Only one strategy delivered the complete package. A monoclonal antibody, BWA3, that neutralizes extracellular histone-H4 and H2A, administered just before and one day after pneumonia induction, reduced neurological deficits, shrank infarct volume, prevented blood-brain barrier breakdown, and curtailed microvascular thrombosis. Crucially, the benefits endured. Over 56 days of follow-up, histone-neutralized mice performed better on neurological scoring, tight rope walking, open field activity, and novel object recognition, and they developed significantly less brain atrophy. Histone blockade also increased the density of microglia and macrophages in the ischemic striatum while reducing their activation, without affecting microglial cell death, and it lowered circulating extracellular histone-H4 without altering NET levels, indicating that the antibody disarms histones rather than preventing their release.

The biology behind this protection fits a growing picture of extracellular histones as potent damage-associated molecular patterns. Once outside the cell, histones injure tissue by activating toll-like receptors and the complement cascade, triggering cytokine and chemokine release through MyD88, nuclear factor-kappa-B, and the NLRP3 inflammasome. In atherosclerosis models, externalized histone-H4 kills vascular smooth muscle cells, recruits more neutrophils, and perpetuates a cycle of NET release that destabilizes plaques, a cycle that histone neutralization can break. Extracellular histones have previously been identified as major mediators of death in sepsis, and administering histones to stroke mice worsens neurological deficits and infarct volume. What is new here is the demonstration that histones are the decisive link between a lung infection and progressive brain injury, and that intercepting them days after the stroke, at the moment pneumonia strikes, can still change the trajectory of recovery.

The clinical implications are tantalizing. Small-molecule inhibitors, inhibitory peptides, and neutralizing antibodies directed against histone-H4 are already in development for other inflammatory conditions, and the new data argue that stroke patients developing pneumonia could be a prime population for such therapies. The study also carries a caution for ongoing trials of intravenous DNase-I in ischemic stroke, three of which are currently registered, since delayed NET degradation increased brain hemorrhages in this model and should be monitored carefully. For now, the work redefines stroke-associated pneumonia not simply as an infection to be cured but as a neutrophil-driven storm whose toxic cargo, the histones, can be intercepted. If the mouse findings translate, the humble proteins that package DNA in every cell nucleus may become one of the most actionable drug targets in post-stroke care.

Subject of Research: Neutrophil-driven inflammatory brain injury and histone neutralization therapy in ischemic stroke complicated by bacterial pneumonia

Article Title: Histone neutralization protects the ischemic brain against the consequences of stroke-associated pneumonia

Article References: Yin, D., Li, A., Mohamud Yusuf, A., Shevchuk, O., Gronewold, J., Thiebes, S., Tertel, T., Wang, C., Hagemann, N., Zhang, Y., Graser, C., Tas, H., Fleischer, M., Kaltwasser, B., Frank, B., Tuz, A. A., Singh, V., Siemes, D., Pylaeva, E., … Hermann, D. M. (2026). Histone neutralization protects the ischemic brain against the consequences of stroke-associated pneumonia. Acta Neuropathologica, 152(1), Article 50. https://doi.org/10.1007/s00401-026-03097-0

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03097-0

Keywords: ischemic stroke, stroke-associated pneumonia, neutrophils, neutrophil extracellular traps, extracellular histones, histone neutralization, blood-brain barrier, microvascular thrombosis, Streptococcus pneumoniae, myeloperoxidase, brain atrophy, neurological recovery

The research, led by teams at the University of Florence and the University of Pisa with international collaborators, focused on neutrophil extracellular traps, or NETs. NETs are web-like structures composed of DNA studded with toxic proteins that neutrophils normally release to immobilize and kill microbes. In recent years, however, biologists have recognized that inappropriate or excessive NET formation, a process called NETosis, contributes to autoimmune conditions, thrombosis and cancer progression. Earlier work had hinted that NETs are present in endometriotic lesions, but the molecular consequences of their presence, and the mechanisms that sustain their production in this disease, remained poorly defined.

To close that gap, the investigators first examined tissue from patients. Using immunofluorescence and immunohistochemistry, they compared endometriotic lesions from ten women with endometrial tissue from ten healthy controls. The lesions showed a marked increase in markers of NETs, including myeloperoxidase, an enzyme packaged into NET webs, and citrullinated histone H3, a chemical signature of the chromatin decondensation that precedes NET release. Masson’s trichrome staining, which dyes collagen blue, revealed significantly greater collagen deposition in the lesions, confirming that fibrosis accompanies the accumulation of these neutrophil-derived structures. The two phenomena, NET burden and scarring, appeared side by side in the same tissue.

The next question was whether the NETs were merely a bystander or an active driver of fibrosis. To find out, the researchers treated human endometriotic epithelial cells and stromal cells, the two main cell types within lesions, with isolated NETs in the laboratory. The response was striking. Epithelial cells underwent epithelial-mesenchymal transition, a developmental program in which tightly adherent epithelial cells lose their identity, gain motility and acquire the capacity to deposit extracellular matrix; this was visible as a loss of E-cadherin and a gain of mesenchymal markers. Stromal cells, meanwhile, shifted toward a myofibroblast-like phenotype, upregulating alpha-smooth muscle actin and fibronectin, hallmarks of activated, matrix-producing cells. In both compartments, NET exposure pushed the cells toward a pro-fibrotic state.

The mechanistic heart of the study lies in a lipid called sphingosine 1-phosphate, or S1P. S1P is a bioactive sphingolipid metabolite that signals through five cell-surface receptors and regulates immunity, vascular integrity and cell survival. The team found that when endometriotic cells were exposed to NETs, they reprogrammed their entire S1P signaling axis. Expression of sphingosine kinase-1, or SK1, one of the two enzymes that synthesize S1P, increased, as did the transporter Spns2, which exports S1P out of the cell, and two of the S1P receptors, S1P2 and S1P3. In other words, the cells not only made more of the lipid but also built the machinery to ship it out and to sense it once it returned.

To test whether this lipid circuit was actually responsible for the fibrotic response, the researchers used genetic silencing and pharmacological tools to interfere with SK1 or with Spns2. When either node of the pathway was disabled, the pro-fibrotic effect of NETs on endometriotic cells was abolished. This loss-of-function result is critical: it demonstrates that S1P synthesis and export are not incidental correlates of scarring but necessary links in the chain connecting neutrophil traps to collagen-producing behavior. The finding elevates S1P metabolism from a general inflammatory marker to a specific, testable driver of endometriosis-associated fibrosis.

Perhaps the most compelling discovery emerged when the direction of communication was reversed. The team collected conditioned media, the nutrient fluid in which endometriotic cells had been cultured, from cells in which S1P metabolism or export had been modulated, and applied these fluids to fresh neutrophils. The media potently influenced NETosis, showing that endometriotic cells stimulate neutrophils to release their traps through S1P-dependent signaling. Combined with the earlier results, this establishes a bidirectional feedback loop: neutrophils release NETs, which push endometriotic cells to produce and export S1P, and the exported S1P in turn drives neutrophils to form more NETs. Each turn of the loop amplifies both inflammation and fibrogenesis, providing a mechanistic explanation for why endometriotic lesions tend to become progressively more fibrotic over time.

To determine whether this circuit operates in the whole organism rather than only in culture dishes, the researchers measured circulating levels of S1P and myeloperoxidase, a NET marker, in the plasma of thirty patients and twenty healthy controls. In patients with endometriosis, the two molecules correlated positively, whereas in healthy women no such relationship existed. This correlation suggests that the S1P-NET axis is active systemically in the disease and raises the possibility that the pair could serve as a blood-based biomarker, offering a less invasive way to assess disease activity than surgery, which remains the gold standard for diagnosis today.

The therapeutic implications are considerable. Because the loop requires S1P synthesis by SK1 and its export through Spns2, both enzymes represent concrete points of intervention. Drugs that modulate S1P signaling already exist in other fields; fingolimod, a functional S1P receptor modulator, is an approved treatment for multiple sclerosis, and SK inhibitors are in development for cancer and inflammation. The present study does not report clinical trials of such agents in endometriosis, but it provides the preclinical rationale for evaluating them. Importantly, targeting S1P metabolism would be a non-hormonal strategy, addressing a major unmet need for patients who cannot tolerate or do not respond to existing hormonal therapy, and it could in principle dampen both NETosis and fibrogenesis simultaneously rather than merely suppressing lesion growth.

Caveats remain, as they do in any translational study. The patient tissue cohort was small, with ten lesions and ten controls in the histological analysis, and the plasma correlation, while statistically meaningful, does not by itself prove causation in humans. The mechanistic work relies on immortalized cell lines and isolated neutrophils, which capture key features of the disease but not its full complexity. Nonetheless, the convergence of patient tissue data, cell-based loss-of-function experiments and circulating biomarker correlations forms an unusually coherent evidence chain. The study also carries a poignant note: it is dedicated to the memory of co-author Asgerally T. Fazleabas, a distinguished reproductive biologist at Michigan State University who contributed to the project before his death. If future work confirms that breaking the S1P-NET loop slows fibrosis in patients, this research may mark the beginning of a shift in how endometriosis is understood, from a primarily hormonal disorder to one in which immune-lipid crosstalk is a central, and druggable, engine of disease progression.

Subject of Research: The role of sphingosine 1-phosphate signaling and neutrophil extracellular traps in fibrosis associated with endometriosis

Article Title: Sphingosine 1-phosphate-driven interplay between neutrophils and endometriotic cells fuels fibrosis in endometriosis: insights into the role of neutrophil extracellular traps

Article References: Prisinzano, M., Seidita, I., Bertilacchi, M. S., Giusti, M., Romeo, L., Nardi, E., Castiglione, F., Schumacher, F., Thomas, D., Kleuser, B., Fambrini, M., Fazleabas, A. T., Petraglia, F., Trincavelli, M. L., Bruni, P., Donati, C., Giacomelli, C., & Bernacchioni, C. (2026). Sphingosine 1-phosphate-driven interplay between neutrophils and endometriotic cells fuels fibrosis in endometriosis: insights into the role of neutrophil extracellular traps. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08971-9

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08971-9

Keywords: endometriosis, neutrophil extracellular traps, NETosis, sphingosine 1-phosphate, sphingosine kinase-1, Spns2, fibrosis, epithelial-mesenchymal transition, myeloperoxidase, inflammation, non-hormonal therapy, biomarkers

NETosis is a relatively recent addition to the immunology lexicon. First recognised as a mechanism for trapping and killing microbes, it involves the formation of neutrophil extracellular traps, or NETs, which are web-like lattices of DNA studded with antimicrobial proteins. The process can unfold in two distinct ways. In vital NETosis, the neutrophil remains alive and functional while deploying its DNA weapon, typically in response to pathogen-associated molecular patterns derived from microbes. In suicidal or lytic NETosis, the cell perishes: its nuclear envelope disintegrates, its plasma membrane ruptures, and DNA chains decorated with citrullinated histones, neutrophil elastase and myeloperoxidase spill into the extracellular space. The molecular choreography is intricate. An enzyme called peptidyl-arginine deiminase 4 citrullinates histones, loosening the grip of chromatin, while granule enzymes translocate to the nucleus to cleave histones further, allowing the genetic material to decondense before its dramatic release.

Although NETosis has been implicated in atherosclerosis and thromboinflammation, its role in chronic heart failure remained underexplored. The research team, led by Sawa Kostin and colleagues, examined left ventricular tissue from 21 patients undergoing orthotopic heart transplantation. The patients fell into three groups matched for age, symptom severity, medication and comorbidities: seven with inflammatory cardiomyopathy following histologically proven myocarditis, seven with idiopathic dilated cardiomyopathy, and seven with ischaemic cardiomyopathy caused by severe coronary artery disease. Crucially, in the ischaemic group the researchers analysed only tissue remote from previous infarcts, ensuring that observed inflammation reflected the failing heart as a whole rather than scarred regions. As controls, they used myocardial samples from five patients with aortic stenosis whose left ventricular function was fully preserved and whose tissue showed no damage, inflammation or fibrosis.

The results were striking. Using immunolabelling for CD66b, a neutrophil marker, the team found that control myocardium contained a median of just 2.48 neutrophils per square millimetre. In the failing hearts, that figure soared to 11.4 cells in dilated cardiomyopathy, 13.9 in ischaemic cardiomyopathy and 15.5 in inflammatory cardiomyopathy, a four- to six-fold increase. To detect NETosis directly, the researchers stained for citrullinated histone 3 and myeloperoxidase, two molecular signatures of NET formation. Confocal microscopy revealed thin, long NET structures, ranging from 5 to 50 micrometres, positive for both DNA and citrullinated histone 3, weaving through the failing myocardium. No such structures appeared in control tissue.

Biochemical and molecular assays corroborated the microscopy. Western blot analysis showed that citrullinated histone 3 protein levels were 4.8-fold higher in inflammatory cardiomyopathy, 4.4-fold higher in ischaemic cardiomyopathy and 2.7-fold higher in dilated cardiomyopathy compared with controls, with all differences statistically significant. Quantitative polymerase chain reaction confirmed that myeloperoxidase messenger RNA was three to four times more abundant in the failing hearts. When the researchers counted neutrophils positive for both CD66b and citrullinated histone 3, they found medians of 7.94 cells per square millimetre in inflammatory cardiomyopathy, 5.51 in dilated cardiomyopathy and 5.79 in ischaemic cardiomyopathy, against just 1.12 in controls. Triple staining for CD66b, citrullinated histone 3 and myeloperoxidase revealed a 4.6- to 6.1-fold increase across all heart failure groups, with no significant differences between aetiologies.

Macrophages told an equally compelling story. These highly plastic cells, which can polarise into classically activated M1-like macrophages that drive inflammation or alternatively activated M2-like macrophages that promote repair and phagocytosis, are among the most active immune participants in cardiac remodelling. Counting CD68-positive cells, the team found a median of 13.3 macrophages per square millimetre in control myocardium, rising to 47.1 in dilated cardiomyopathy, 55.4 in ischaemic cardiomyopathy and 69.4 in inflammatory cardiomyopathy. Remarkably, macrophage numbers correlated very strongly with neutrophil counts, with a Spearman coefficient of 0.918, suggesting the two cell populations accumulate in lockstep within the diseased heart.

Phenotyping revealed a decisive shift. In control tissue, only about 3 percent of macrophages displayed the M1-like profile, identified by co-expression of CD68 with tumour necrosis factor alpha or interleukin-6, while roughly 6.5 percent were M2-like, marked by CD206 or arginase-1. In the failing hearts, M1-like macrophages dominated: 78.5 percent in inflammatory cardiomyopathy, 54.5 percent in ischaemic cardiomyopathy and 53.2 percent in dilated cardiomyopathy. M2-like macrophages also increased, reaching roughly 21 to 23 percent, but never matched the proinflammatory surge. The resulting M1-to-M2 ratio, a measure of inflammatory balance, stood at 3.19 in inflammatory cardiomyopathy and around 2.5 to 2.6 in the other groups, compared with just 0.63 in controls, all differences statistically significant.

The pivotal finding emerged when the researchers correlated NETosis with macrophage polarisation. The percentage of M1-like macrophages correlated positively and significantly with the number of neutrophils undergoing NETosis, with a correlation coefficient of 0.79 for triple-positive citH3/MPO/CD66b cells and 0.68 for citH3/CD66b cells. In contrast, M2-like macrophages showed no meaningful association with NETosis, with coefficients near zero and non-significant p-values. Triple immunolabelling for citrullinated histone 3, tumour necrosis factor alpha and CD206 provided visual confirmation: NET-forming neutrophils were consistently surrounded by far more TNF-alpha-positive M1-like macrophages than CD206-positive M2-like cells.

What might this interplay mean mechanistically? Prior work offers intriguing clues. Co-culture experiments have shown that both M1- and M2-like macrophages can degrade NETs, with M1-like cells dominating the early phagocytic response and M2-like cells completing clearance later. Studies in acute pulmonary ischaemia-reperfusion injury have described a mutual feedback loop in which NETosis drives M1-like polarisation, which in turn promotes further NETosis. The authors suggest that in chronic heart failure this reciprocal interaction may create a positive feedback loop that sustains low-grade myocardial inflammation, a recognised hallmark of the disease. Alternatively, the M1 skewing could represent a compensatory attempt to clear excessive NETs, one that fails to suppress NET formation itself. The concurrent rise in M2-like macrophages, albeit more modest, may reflect involvement in clearing dead cardiomyocytes and contributing to fibrosis, given that the failing heart loses an estimated 20 percent of its cardiomyocytes each year in terminal stages.

The authors are careful to note that correlation does not establish causation, and that the observed associations may be consequences of chronic heart failure rather than drivers of it. The study’s limitations include the small number of patients, the differing aetiologies across groups and considerable interindividual variability. Nevertheless, the consistency of the findings across inflammatory, dilated and ischaemic forms of the disease, and the earlier observation that neutrophil and macrophage accumulation precedes overt heart failure in compensated hypertrophy, lend weight to the idea that this immune axis matters. Recent research also implicates extracellular vesicles released by injured cardiomyocytes in promoting neutrophil-driven inflammation and macrophage polarisation, suggesting multiple routes by which tissue damage could ignite the NETosis-macrophage circuit. If future studies confirm a causal role, inhibiting NETosis or restoring the balance between M1- and M2-like macrophages could become genuine therapeutic strategies for chronic heart failure, a condition that still lacks treatments targeting its inflammatory underpinnings. For now, the study provides a rigorous anatomical and molecular map of that circuit in human tissue, and a clear hypothesis for the next generation of experiments.

Subject of Research: The association between neutrophil extracellular trap formation and proinflammatory macrophage polarisation in human heart failure

Article Title: Increased NETosis in Patients With Heart Failure Is Associated With Macrophage Activation Towards a Proinflammatory Phenotype

Article References: Kostin, S., Cabrera‐Fuentes, H. A., Richter, M., Krizanic, F., Ritter, O., Boisvert, W. A., Preissner, K. T., Kelesidis, T., Siasos, G., & Pagonas, N. (2026). Increased NETosis in Patients With Heart Failure Is Associated With Macrophage Activation Towards a Proinflammatory Phenotype. Journal of Cellular and Molecular Medicine, 30(17), Article e71306. https://doi.org/10.1111/jcmm.71306

Image Credits: AI Generated

DOI: 10.1111/jcmm.71306

Keywords: heart failure, NETosis, neutrophils, macrophages, M1 polarisation, myocardial inflammation, citrullinated histone 3, myeloperoxidase, cardiac remodelling, innate immunity, cardiomyopathy, immunohistochemistry

The research team, led by investigators at the University Hospital Zurich, examined 112 patients who died or suffered a recurrent myocardial infarction within one year of their initial event, matching each case one-to-one with a control patient of the same age, sex, infarct subtype, symptom-onset timing, and recruiting site. All blood samples were drawn within 24 hours of symptom onset, capturing the inflammatory landscape at a moment when standard clinical markers had often not yet begun their climb. Compared with controls, the patients who later experienced adverse outcomes had significantly higher plasma concentrations of IL-8, cell-free DNA, and myeloperoxidase, along with a higher neutrophil-to-lymphocyte ratio.

These three soluble markers tell a coherent biological story. Interleukin-8, also known as CXCL8, is released by endothelial cells, monocytes, and macrophages at the first sign of injury and creates a chemical gradient that draws neutrophils to the damaged myocardium. Once there, neutrophils expel neutrophil extracellular traps, web-like structures composed of cell-free DNA studded with enzymes such as myeloperoxidase. Although these traps serve a protective purpose against pathogens, in the setting of atherosclerosis they can activate platelets and coagulation factors, potentially worsening the very thrombotic process that caused the infarction. The simultaneous elevation of IL-8, cfDNA, and MPO in patients who fared poorly points to a hyperactive IL-8 and NET axis operating in the hours immediately after coronary occlusion.

Perhaps the most striking finding concerns timing. When patients were stratified by how quickly they reached the hospital after symptoms began, IL-8 levels were already significantly elevated in those presenting within three hours, whereas high-sensitivity troponin T only became clearly discriminative in late presenters beyond six hours. Within the hyper-acute window, IL-8 outperformed troponin, NT-proBNP, C-reactive protein, and kidney function markers in distinguishing future events from stable outcomes. After adjusting for these confounders, the association between IL-8 and the combined endpoint of death or recurrent infarction was strongest among early presenters, with an odds ratio of 2.65 for patients arriving within six hours of symptom onset.

The temporal analysis extended to the prognosis itself. When the researchers focused on early adverse events occurring within thirty days, the association between IL-8 and risk strengthened markedly, reaching an adjusted odds ratio of 4.47. A formal statistical test confirmed a significant interaction between IL-8 levels and symptom-onset time, meaning that the predictive value of this chemokine is genuinely tied to how early in the disease course the measurement is taken. This finding carries practical implications, because the first hours after symptom onset have long been a diagnostic blind spot in which traditional biomarkers lag behind the rapidly evolving pathology.

Within the group of patients who experienced adverse outcomes, those who died had higher IL-8 and cfDNA levels than those who survived with a recurrent infarction, suggesting that fatal outcomes are characterized by an even more intense neutrophil-driven inflammatory response. The neutrophil-to-lymphocyte ratio, a simple calculation available from any standard blood count, was likewise higher in the death subgroup, echoing results from large trials such as CANTOS, where each quartile increase in this ratio corresponded to a roughly twenty percent rise in major adverse cardiovascular events.

Unsupervised clustering of the inflammatory data added another layer of insight. When patients were grouped according to their combined profiles of IL-8, cfDNA, neutrophil-to-lymphocyte ratio, and high-sensitivity C-reactive protein, one cluster was significantly enriched in patients presenting with acute heart failure, defined clinically as a Killip Class of two or higher, and in those who ultimately died. This overlap between systemic inflammation and acute heart failure suggests that high IL-8 levels may partly reflect the mechanistic basis of pump dysfunction rather than merely accompanying it, although the observational design of the study cannot resolve whether inflammation causes heart failure or simply mirrors it.

The researchers also tested whether adding IL-8 to the widely used GRACE 2.0 risk score would improve its predictive accuracy. After rigorous cross-validation, neither IL-8 alone nor the combined panel of inflammatory markers produced a statistically significant improvement over the existing score for the overall cohort, likely because the score already captures much of the relevant risk and because late presenters diluted the hyper-acute signal. The authors therefore frame IL-8 not as a universal upgrade to existing risk tools but as a precision-medicine candidate for the specific subgroup of patients who present within hours of symptom onset.

Several caveats temper the enthusiasm. The study was observational and matched by design, so it cannot establish causality, and the lack of an IL-8 gene in mice complicates experimental efforts to probe the chemokine’s role directly. Genetic association studies hint that polymorphisms in the IL-8 promoter influence both circulating levels and acute coronary syndrome risk, but larger studies will be needed to determine whether IL-8 drives worse outcomes or simply reports on them. The authors also note that no clinical cutoff value for IL-8 can be proposed from a case-control design, and external validation in an independent cohort remains essential.

Even so, the prospect of a point-of-care IL-8 test, paired with the humble neutrophil-to-lymphocyte ratio, offers a tantalizing vision for emergency cardiology: a rapid, early, and biologically grounded assessment of risk during the very first hours of a heart attack, when every clinical decision carries the greatest weight. Therapies targeting IL-8 signaling are already being explored in oncology, and this study adds urgency to investigating whether similar approaches might one day quiet the inflammatory storm that follows myocardial infarction.

Subject of Research: Interleukin-8 and neutrophil-related biomarkers as prognostic markers for one-year mortality after acute myocardial infarction

Article Title: Interleukin-8 and other neutrophil-related biomarkers are associated with 1-year mortality in patients with acute myocardial infarction

Article References: Wang, Y.-J., Matter, M. A., Rossi, V. A., Heg, D., Costantino, S., Paneni, F., Gallino, C., Stähli, B. E., Räber, L., Windecker, S., Mach, F., Gencer, B., Klingenberg, R., Rodondi, N., Nanchen, D., Levesque, M. P., Demler, O. V., Ruschitzka, F., & Matter, C. M. (2026). Interleukin-8 and other neutrophil-related biomarkers are associated with 1-year mortality in patients with acute myocardial infarction. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03026-x

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03026-x

Keywords: interleukin-8, acute myocardial infarction, neutrophils, neutrophil extracellular traps, cell-free DNA, myeloperoxidase, neutrophil-to-lymphocyte ratio, biomarkers, mortality, inflammation, GRACE 2.0, cardiology